01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan (ORPH) – Early adopters signed for Genomic Health DataBANK November 25, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce it has signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform. The platform is expected to be completed and rolled out in Q1 2020. The five companies signed up to the Genomic Health DataBANK platform will ensure the database is ‘fit-for-purpose’ from a pharmaceutical and data analysis perspective ahead of the first patient data upload. This builds…

Continue reading

Open Orphan (ORPH) Contract signed with Carna Bioscience November 18, 2019 – Posted in: Open Orphan (ORPH)

  Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a contract with Carna Bioscience (“Carna”) (www.carnabio.com) for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next twelve  months. Carna is a Japanese company specialising in kinase biology, developing innovative treatments against cancer and immune disorders. This contract sees Venn Life Sciences (“Venn”), part…

Continue reading

Open Orphan (ORPH) to attend Jefferies 2019 London Healthcare Conference November 15, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending the Jefferies 2019 London Healthcare Conference on 20th-21st November 2019 in London, UK. The conference will be attended by a range of international healthcare executives and institutional investors who will gather to address near and long-term investment opportunities and to discuss the mechanisms driving global healthcare. Open Orphan’s Chief Executive Officer, Cathal Friel, will be in attendance and will…

Continue reading

Open Orphan’s (ORPH) Maurice Treacy Hosts Value the Markets Webinar October 24, 2019 – Posted in: Open Orphan (ORPH)

  Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company’s Chief Commercial Officer, Maurice Treacy, will be hosting a webinar alongside Value the Markets on Wednesday 30th October 2019 at 19:00 (UK time). Maurice Treacy will take the opportunity to update existing and potential shareholders on Open Orphan and will provide an insight on the Company’s Genomic Health Data platform, Europe’s first rare disease, advocacy-led genomic database. Maurice will also discuss how and why…

Continue reading

Open Orphan plc (ORPH) Investor Event Attendance and Presentation October 21, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at The London Investor Show at Novotel London West, London, W6 8DR this Friday 25th October 2019. Maurice Treacy, Open Orphan’s Chief Commercial Officer, will be in attendance and will be presenting in Conference Room 1 from 11:50am – 12:20pm. Afterwards there will be an opportunity for existing and potential shareholders to discuss the Company’s business plans…

Continue reading

Open Orphan (ORPH) – CRUX Asset Management Ltd increase Holding(s) in Company October 1, 2019 – Posted in: Open Orphan (ORPH)

TR-1: Standard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Open Orphan PLC 1b. Please indicate if the issuer is a non-UK issuer  (please mark with an “X” if appropriate) Non-UK issuer 2. Reason for the notification (please mark the appropriate…

Continue reading

Global Orphan Drugs Market Growth, Trends and Forecasts 2019-2024 – Business Wire August 19, 2019 – Posted in: Open Orphan (ORPH)

Article from BusinessWire.com The orphan drugs market is expected to register a CAGR of 11.5% over the forecast period Factors that are responsible for the growth of this market include market exclusivity for orphan drug developers, the rising prevalence of rare diseases, and favorable government policies. The market is expected to register an increased CAGR during the forecast period because the prevalence of rare diseases among the global population has been increasing in recent years.…

Continue reading